| Name | Title | Contact Details |
|---|
NCM Publishers is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Transitions Optical we help people live more vibrant lives by enhancing their vision and the way they perceive light. We were the first to successfully commercialise a plastic photochromic lens in 1990 and our talented people continue to make significant advances in colour science and lens materials, creating a better photochromic experience that`s available to more people. Through our partnerships with optical industry leaders, we offer adaptive solutions in the widest selection of designs and materials, covering hundreds of lens combinations. Our industry leading eyeglass brands are well known; Transitions® Signature®, Transitions® Vantage® and Transitions® XTRActive®. And we don`t stop there; we also make adaptive sunwear and motorcycle helmet shields. Transitions Optical is part of the Essilor Group.
St. Luke's Hospital and Health Network is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bethlehem, PA. To find more information about St. Luke's Hospital and Health Network, please visit www.slhn.org
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
Medical Modalities is a Concord, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.